HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH"). more info >>
HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases more info >>
2016年啟動的新一輪藥政改革吹響了中國醫藥產業“由仿到創”升級的衝鋒號角,也掀起了創新藥產業發展的第一波浪潮,大量的資本和人才被吸引湧入這個新興的創新產業,通過license in、fast follow、me too/better等性價比相對較高的研發模式為整個行業帶來了充足的創新藥專案,明顯改善了中國民眾的創新藥可及性。 more info >>
2016年启动的新一轮药政改革吹响了中国医药产业“由仿到创”升级的冲锋号角,也掀起了创新药产业发展的第一波浪潮,大量的资本和人才被吸引涌入这个新兴的创新产业,通过license in、fast follow、me too/better等性价比相对较高的研发模式为整个行业带来了充足的创新药项目,明显改善了中国民众的创新药可及性。 more info >>